DCCR benefits for PWS confirmed in Magel2 deficient mice with improved endurance capacity

FEB 2018 – Diazoxide Choline Controlled Release (DCCR) is currently being developed by Soleno Therapeutics following a successful phase 2 trial in PWS patients which observed improvements in hyperphagia, a reduction of body fat and increase in lean body mass. They are advancing DCCR into a phase 3 clinical development program which is due to start recruiting from March 2018.

A newly published study at the University of Alberta tested whether chronic diazoxide administration can reduce fat mass and improve metabolism in mice lacking MAGEL2, a gene inactivated in PWS. The mice were rendered obese by high fat diet feeding, then provided diazoxide while being maintained on a high fat diet. Treatment with diazoxide reduced weight and body fat, lowered blood glucose and improved endurance capacity. Read More  >

DCCR is looking very promising as a potential future treatment for hyperphagia in PWS.